Pathophysiology of Fibrodysplasia Ossificans Progressiva
Published on: May 27, 2026
Pathophysiology of Fibrodysplasia Ossificans Progressiva featured image
  • Article reviewer photo

    Lara Bower

    Bachelor of Science in Biomedical Science

Introduction

Fibrodysplasia Ossificans Progressiva (FOP), also known as Myositis Ossificans, is a rare genetic disease that affects approximately one in two million people worldwide. In this condition, the body responds to illness and minor injury not by repairing tissue in the usual way, but by forming bone in places where it does not belong. This means that muscles, tendons, and even ligaments can turn into bone: over time, a secondary skeleton begins to develop, leading to a progressive reduction in movement and interfering with important functions such as breathing, eating, and speaking.

In FOP, extra bone forms in places where it should not be present, particularly across the shoulders, neck, and back. This bone grows in sheets and bridges, locking joints in place and making movement extremely difficult. Over time, FOP progressively replaces soft tissues with hard bone, which is why even simple movements such as turning the head or lifting the arms can become impossible.

Studying the pathophysiology of FOP allows scientists to understand the biological foundations of the disease and also informs broader research into musculoskeletal health.

What Causes FOP?

In the majority of cases, FOP is caused by a point mutation in a gene called ACVR1. Under normal conditions, ACVR1 controls how and when bone forms. In patients with FOP, the mutation causes the body to misinterpret certain signals: instead of repairing muscle after an injury, it mistakenly creates new bone. This process is known as heterotopic ossification, which refers to bone growing where it does not belong.

The most common mutation in FOP is R206H. At position 206 in the protein sequence, the amino acid arginine has been substituted by histidine. This causes the body to respond incorrectly to a natural protein called activin A, which normally inhibits bone formation. In FOP, the mutated receptor interprets activin A as a signal to grow bone rather than to suppress it.

The Genetics Behind FOP

At the heart of FOP is a single gene, ACVR1. Genes, composed of DNA, contain the instructions for building proteins and regulating biological processes throughout the body. Under normal conditions, ACVR1 instructs cells how to respond to growth signals that regulate bone development. In patients with FOP, however, a single nucleotide change causes the ACVR1 receptor to become constitutively active, switching on when it should remain silent.

This error has significant consequences. Instead of remaining inactive until bone growth is genuinely required, the receptor behaves as though the body is continuously signalling for new bone. Even signals that normally suppress bone formation, such as activin A, which acts within the bone morphogenetic protein (BMP) pathway, are misinterpreted as commands to produce more bone. The BMP pathway is a cell signalling system that governs the growth and development of bone and other tissues. This molecular miscommunication sets off a cascade of events that drives disease progression.

Flare-Ups and Triggers

FOP progression is neither linear nor predictable. Instead, the disease advances in episodes known as flare-ups. These can present with sudden inflammation, swelling, pain, and stiffness, and are often triggered by something as minor as a bump, a bruise, or an intramuscular injection. Viral illnesses, such as influenza, can also be sufficient to initiate a flare-up. In some cases, patients experience episodes with no identifiable trigger at all.

How New Bone Forms

Under normal conditions, bone forms through a process called ossification. There are two main pathways. In intramembranous ossification, bone develops directly from soft connective tissue; this is how flat bones such as the skull form. In endochondral ossification, which accounts for the formation of most bones (including those of the limbs), the body first creates a cartilage template that is gradually replaced by true bone. This entire process is regulated by specialised cells: osteoblasts build bone, whilst osteoclasts resorb it when necessary. Ossification is required not only for growth, but also for fracture repair and the renewal of existing bone.

In patients with FOP, however, the process by which extra bone forms closely resembles embryonic skeletal development. It progresses through the following stages:

  • Inflammation: The affected area becomes swollen, warm, and painful
  • Fibrovascular proliferation: The body deposits fibrous connective tissue richly supplied with new blood vessels
  • Chondrogenesis: This tissue gradually transforms into cartilage, which acts as a temporary scaffold
  • Ossification: The cartilage mineralises and hardens into permanent bone

Once formed, this bone cannot be safely removed. Surgery to excise it almost invariably triggers further bone growth in surrounding areas.

How the Disease Progresses

FOP rarely affects the body simultaneously across all regions. Instead, it follows a recognisable anatomical pattern. In most children, the first signs appear in the neck and shoulders, with involvement spreading progressively to the back, trunk, and limbs. Almost all patients are born with shortened or malformed great toes, which can serve as an important early diagnostic indicator.

As the disease advances, bridges of ectopic bone lock joints together. Movements such as raising an arm, bending at the waist, or turning the neck gradually become impossible. By early adulthood, many patients require a wheelchair for mobility.

Factors That Exacerbate FOP

Although the ACVR1 mutation is the primary cause of FOP, several factors are known to worsen the condition or precipitate flare-ups:

Injury or Trauma

Minor injuries such as bumps, bruises, or muscle strains can trigger a flare-up. More significant trauma, including falls or surgery, can cause rapid and extensive ossification.

Intramuscular Injections

Vaccines or medications administered intramuscularly can trigger unwanted bone growth at the injection site. For this reason, people with FOP are generally advised to avoid intramuscular injections wherever possible.

Surgery or Invasive Procedures

Attempts to remove ectopic bone or perform other invasive procedures, such as biopsies or dental surgery, almost always result in further bone formation. Even muscle biopsies or deep dental work can precipitate a flare-up.

Viral Infections and Illness

Infections accompanied by fever and systemic inflammation can activate the immune system in ways that contribute to flare-ups. Many patients report increased symptoms following illness.

Muscle Fatigue or Overuse

Excessive physical activity or intense exercise can stress muscles and provoke inflammation, thereby triggering a flare-up.

Treatments and Care

There is currently no cure for FOP. The primary goals of treatment are to reduce inflammation, prevent trauma, and slow the progression of new bone growth. Current and emerging treatment options include:

  • Glucocorticoids: Drugs such as prednisone can help reduce inflammation if administered early in a flare-up, though their benefit is temporary
  • Anti-inflammatory agents: Corticosteroids suppress immune overactivity, while NSAIDs (such as ibuprofen) inhibit enzymes involved in pain and inflammation
  • Palovarotene (Sohonos): The first FDA-approved treatment for FOP, palovarotene works by activating a specific receptor that prevents mesenchymal cells from differentiating into bone, thereby reducing abnormal bone growth
  • Supportive care: Avoiding unnecessary injections, reducing fall risk, and maintaining gentle physical activity can help prevent additional trauma and limit the frequency of flare-ups

Complications

The ectopic bone that forms in FOP can give rise to serious complications. Bone growth around the thorax can restrict lung expansion, severely impairing respiratory function. Progressive loss of joint mobility leads to increasing dependence and difficulty performing everyday activities such as eating and speaking.

The median lifespan of patients with FOP is approximately 56 years. The leading causes of premature death are respiratory complications, including thoracic insufficiency syndrome, in which abnormal bone growth restricts chest wall movement, and pneumonia.

Summary

Fibrodysplasia Ossificans Progressiva (FOP) is a rare musculoskeletal condition caused by a mutation in the ACVR1 gene. This mutation results in heterotopic ossification: the abnormal growth of bone within muscles and connective tissue. The disease progresses in flare-ups, each of which begins with inflammation and culminates in permanent bone formation. It typically presents in childhood, follows a recognisable pattern of anatomical progression, and eventually causes severe immobility alongside complications affecting breathing and eating. There is no cure at present, but ongoing research is identifying targeted therapies with the potential to slow disease progression.

References

  1. Nilsson OS. Editorial: Heterotopic ossification. Acta Orthopaedica Scandinavica [Internet]. 1998 [cited 2025 Sep 30]; 69(2):103-6. Available from: https://actaorthop.org/actao/article/view/20536
  2. Miao J, Zhang C, Wu S, Peng Z, Tania M. Genetic abnormalities in Fibrodysplasia Ossificans Progressiva. Genes & Genetic Systems. 2012; 87(4):213-9.
  3. Penn Medicine. Fibrodysplasia ossificans progressiva (FOP) [Internet]. [cited 2025 Oct 2]. Available from: https://www.pennmedicine.org/conditions/fibrodysplasia-ossificans-progressiva
  4. Wattal A. Rare Disease Digest [Internet]. 2024. FOP: When Muscles Turn to Bone; [cited 2025 Oct 3]. Available from: https://medium.com/rare-disease-digest/when-muscles-turn-to-bone-e6cfd34ba6a4
  5. Bogue DD. Fibrodysplasia ossificans progressiva - Knowledge Hub. GeNotes [Internet]. [cited 2025 Oct 3]. Available from: https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/fibrodysplasia-ossificans-progressiva/
  6. Heterotopic Ossification (HO) | Nuffield Health [Internet]. [cited 2025 Oct 2]. Available from: https://www.nuffieldhealth.com/conditions/heterotopic-ossification
  7. Hatsell SJ, Idone V, Wolken DMA, Huang L, Kim HJ, Wang L, et al. ACVR1 R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015; 7(303):303ra137.
  8. Lin H, Shi F, Gao J, Hua P. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator. Biosci Rep [Internet]. 2019 [cited 2025 Oct 3]; 39(8):BSR20190377. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680371/
  9. How to recognise FOP flare-ups | Focus on FOP [Internet]. [cited 2025 Oct 3]. Available from: https://www.focusonfopus.com/fop-flare-ups
  10. Breeland G, Sinkler MA, Menezes RG. Embryology, Bone Ossification. In: StatPearls [Internet]. StatPearls Publishing; 2023 [cited 2025 Oct 3]. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK539718/
  11. Martelli A, Santos AR. Cellular and morphological aspects of fibrodysplasia ossificans progressiva. Organogenesis [Internet]. 2014 [cited 2025 Oct 3]; 10(3):303-11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750545/
  12. Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby R, Kitterman JA, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol [Internet]. 2008 [cited 2025 Oct 3]; 22(1):191-205. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2424023/
  13. Gencel D, Erbil NN, Demiryurek S, Demiryurek AT. Current and emerging treatment modalities for fibrodysplasia ossificans progressiva. Expert Opinion on Pharmacotherapy [Internet]. 2024 [cited 2025 Oct 3]; 25(16):2225-34. Available from: https://www.tandfonline.com/doi/full/10.1080/14656566.2024.2422548
  14. Fibrodysplasia Ossificans Progressiva: Causes, Symptoms, Treatment, Outlook. Cleveland Clinic [Internet]. [cited 2025 Oct 3]. Available from: https://my.clevelandclinic.org/health/diseases/24476-fibrodysplasia-ossificans-progressiva
  15. Research C for DE and. FDA approves first treatment for Fibrodysplasia Ossificans Progressiva. FDA [Internet]. 2023 [cited 2025 Oct 3]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-fibrodysplasia-ossificans-progressiva
  16. Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010; 92(3):686-91.
Share

Tejinder Kaur

arrow-right